BSI Life Sciences Announces Strategic Partnership with Leading Chinese Pharma IT Distributor CloudScientific

The collaboration will open the market for BSI’s eClinical software solutions in China

BADEN, SWITZERLAND, March 30, 2022 – BSI today announced that it has partnered with Shanghai-based pharma IT distributor CloudScientific Technology to launch its flagship products, BSI Clinical Trial Management System (CTMS) and BSI eTMF (electronic Trial Master File) in China, including Hong Kong and Macau. This strategic move is intended to leverage one of the fastest growing ecosystems in life sciences worldwide, with a pharmaceutical market second only to the U.S. in 2020.

According to Jan Nielsen, BSI’s community manager for life sciences, the partnership will support the continued growth of the software house and increase its global reach. “The collaboration agreement we signed with CloudScientific is a major achievement for us, and surely a win for our partner. We are proud and thankful for the opportunity to work with a well-renowned distributor to build our presence in China,” commented Nielsen.

Trusted by 900+ clients in life sciences and clinical R&D, including many of the largest global pharma companies, CloudScientific is a leading implementation and distribution partner, having helped multiple businesses grow from zero to multimillion-dollar revenue in the Chinese market. Over the past 11 years, its YOY growth averaged 30%, with an impressive 70% in 2020. “We are pleased BSI chose us to sell its digital solutions to private pharmaceutical enterprises and academic research institutions in China,” said CloudScientific CEO and founder Jack Lin. “We already have several CTMS leads in the pipeline and I’m confident we’ll close the first deals at the latest by the end of Q3 this year. Simply, the Chinese pharmaceutical market is huge, and so is the demand for eClinical software,” continued Lin.

BSI’s CEO Markus Brunold also celebrated the partnership and anticipated excellent results. “We are delighted to be working with CloudScientific and look forward to a fruitful collaboration. I’m sure this strategic move will not only help us acquire new customers, but also let more prospects know about BSI’s CTMS and eTMF and their great potential to accelerate the time to market of drugs and medical devices,” he remarked.